Aptamer Inhibitor of Von Willebrand Factor Induces Thrombolysis and Improves Vascular Patency Upon Immediate and Delayed Treatment of Stroke in an in vitro Microfluidic Model Read More
isth 2022 Effect of Novel Thrombolytic Aptamer BB-031 on Microfluidic Thrombolysis and VWF Function Dose-Response Read More
MDPI Dose-Dependent Von Willebrand Factor Inhibition by Aptamer BB-031 Correlates with Thrombolysis in a Microfluidic Model of Arterial Occlusion Read More
AHA Journals Abstract 45: Vwf Inhibitor Lyses Middle Cerebral Artery Occlusion After 6 Hours Of Large Vessel Occlusion Stroke Read More
AHA Journals Abstract 187: Reversible Aptamer Inhibition of Von Willebrand Factor is a Potent Thrombolytic and Ameliorates Stroke Burden Following Vascular Injury Compared to Recombinant Tissue Plasminogen Activator Read More
AHA Journals Abstract WP99: Reversible VWF Inhibitor Reduces Stroke Volumes Compared to TPA in Canine Model of Large Vessel Occlusion Stroke Read More
ScienceDirect Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels Read More
AHA Journals Abstract 522: VWF Inhibition by an RNA Aptamer Improves Functional Outcome Compared to rTPA in Ferric Chloride-induced Carotid Artery Thrombosis in Mice Read More
AHA Journals Abstract 16728: Translating Thrombolytic Efficacy of Von Willebrand Factor Aptamer Inhibition From a Small to Large Animal Model of Carotid Occlusion Read More
